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Abstract
Here, we present results from two independent studies carried out using Neuromolecular Imaging (NMI) with
miniature BRODERICK PROBE® biosensors. In the first study, we imaged neurotransmitters and neurochemicals
in human epilepsy patients intraoperatively during early and late neurodegeneration. In the second study, we
imaged neurotransmitters and neurochemicals in an experimental murine model using animals with and without
neurodegeneration caused by Parkinson’s disease (PD). We compared our results derived from animals with
lesioned group (PD) with non-lesioned group (non-PD), using the same in vivo NMI paradigm. NMI biotechnology
enabled neurotransmitters, neuropeptides and neurochemical imaging of dopamine (DA), serotonin (5-HT),
homovanillic acid (HVA), L-tryptophan (L-TP), dynorphin A (DYN A) and somatostatin (SRIF). Each neurotransmitter
and neurochemical was imaged at its respective signature i.e., its electroactive oxidation/half-wave potential.
Results showed neuropeptide signatures of DYN A and SRIF as common biomarker molecules following late
neurodegeneration in epilepsy patients and in PD animal models. Placing these two studies together allowed us to us
to provide a new hypothesis about a possible biomarker link between the two neurodegenerative diseases, epilepsy
and PD. Interestingly, this biomarker link, to our knowledge has not been observed previously. These findings will
provide new strategies for better diagnoses, detection of and protection against epilepsy and Parkinson’s disease.
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Introduction
Progressive cell death in brain neuronal circuits occurs far too often
from brain injuries caused by diseases such as Epilepsy, Parkinson’s
disease and Alzheimer’s disease. Epilepsy is a neurological disorder
characterized by repeated seizures over time [1]. In this disorder,
the brain exists in an excitable state, increasing neuronal firing rates
resulting in abnormally repeated signals accompanied by seizures.
Epilepsy may result due to various causes such as stroke, dementia,
traumatic brain injury, infections (meningitis, encephalitis, and AIDS),
brain tumor, brain injury and congenital brain defect.
Parkinson’s disease (PD) is the second most common progressive
neurodegenerative disease in America [2]. It is characterized by the
formation of Lewy bodies and Lewy neurites in dopaminergic (DA)
neurons of substantia nigra pars compacta (SNpc) of brain. Symptoms
include progressive impaired movement as (a) uncontrollable resting
tremors (b) bradykinesia, (c) muscle rigidity and (d) postural instability.
Consistent loss of DA neurons results in the depletion of dopamine
level of brainstem and striatal projections, involved in motor function
of CNS.
Several animal model studies have been conducted to provide
further insight into PD and its therapies. However, more experimental
approaches are required to elucidate the precise mechanism of action
of PD involved with DA neurons in nigrostriatal pathways. One of the
major obstacles in the human studies of PD is that brain materials from
early or untreated PD patients are unavailable. In addition, there are
minimal amounts of animal studies with few published reports to date
about in vivo dynamic release of neurotransmitters, neurochemicals
and/or neuropeptides in PD animals. Neuromolecular Imaging (NMI)
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is the first in vivo, real time imaging technique using BRODERICK
PROBE® biosensor to image concentrations of different critical
neurotransmitters involved in stroke, epilepsy and Parkinson’s disease.
Here, we present studies that are primarily focusing over the real
time changes associated with brains following neuro-degeneration in
human epilepsy patients (early v/s late neurodegeneration) and PD v/s
non-PD animal models. We are the first to demonstrate appearance
of neuropeptides as hallmark of neurodegeneration and related
biomarkers for epilepsy and PD.

Principle of neuromolecular imaging
Figure 1 illustrates the NMI setup using BRODERICK PROBE®
biosensor: These biosensors have been tested in controlled studies
and details of NMI biotechnology and circuitry are already published
[3-13]. NMI works on utilizing electron transfer kinetics by selecting
an image of a specific neurochemical or neurotransmitter molecule
at an electroactive oxidation/half wave potential. Specific biosensor
properties such as hydrophobicity, hydrophilicity, side chains of amino
acids of biosensor formulation determine current derived from electron
transfer kinetics upon interaction with specific neurotransmitters and
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The BRODERICK PROBE®
for human and animal studies:

size of indicator electrode, electron transfer and Faraday’s constant are
described below in term of derived equations:

Q = nFVC0 R
i = dQ / dt
i = nFVdCR ,t / dt
where:

Applies potential to
sensor

Sensor detects
neurochemical
concentrations in
brain tissue

Neurochemical
signatures at
specific potentials
imaged by
hardwaresoftware
interface

Figure 1: Schematics of NMI setup. BRODERICK PROBE® is implanted to
live brain tissue and then externally connected to the potentiostat to apply
potential. Upon interaction with specific neurochemical, the BRODERICK
PROBE® transfers its signature electroactive oxidation potential to hardwaresoftware interface for data interpretation and recording.

neuropeptides. The electroactive signature for each molecule is detected
by a detector/potentiostat in subunits of volts and amperes, depending
upon the type of electronic circuitry chosen in the potentiostat for a
particular study. Potentiostat is connected to an external chart recorder
to record signals obtained in form of signature oxidation/half wave
potential. For both circuitry i.e., linear or semi-differential/semiderivative, x-axis represents voltage in millivolts and y-axis represents
current in microamperes.
In vivo studies of brain neurotransmitters based on electrochemistry
have been in progress [14-16] and advancements have been made in
voltammetry and microvoltammetry using carbon fiber electrodes
[17,18]. The basic electrochemical principles of voltammetry are listed
below:
• To measure the current as a function of applied voltage, when an
electroactive species undergo redox reaction at a characteristic redox
potential.
• Formulae: O+ne-↔R, where, ne=number of electrons,
O=oxidation, R=reduction.

V=volume of the diffusion layer on the electrode of measurement
n=number of transferred electrons
F=Faraday’s Constant
Co=initial concentration

Material and Methods
NMI, intra-operative clinical studies in epilepsy patients
NMI, based on electrochemical principles, has made major
advances in the field of nanobiotechnology, science and medicine. For
example, one of these cutting-edge advancements made by NMI and the
BRODERICK PROBE® is in the field of human epilepsy intraoperatively
in NYU Tisch Hospital with Institutional Review Board (IRB) approval
(Figure 2).
Studies in real time with NMI and BRODERICK PROBE®
biosensors begin with electroencephalographic (EEG) monitoring
wherein the site of cortical resection is defined with subdural grid
epilepsy electrodes which are placed on the surface of the brain and
epilepsy strip electrodes are placed subtemporally.
Then, BRODERICK PROBE® biosensors, with a diameter over
five times smaller than epilepsy depth electrodes for invasive EEG, are
placed by direct visualization in the exposed cortical region with and
without epileptic spike activity in regions destined for resection.
About six to ten recordings with γ-irradiated [11.6-12.7 kilograys
(kGys)], laminar biocompatible carbon-based BRODERICK PROBE®

• Current produced by specific redox reaction is directly
proportional to concentration of neurotransmitter, given by the Cottrell
equation described below:

DA

where:
o=concentration of electroactive species oxidized
i=current at time, t
n=number of electron transfers, eq/mol
F=Faraday’s constant, 96486 C/eq
A=electrode area, cm2

Current (pAs-1/2) d1/2l/dt1/2

it = nFACo Do1/2 / 3.141/2 t1/2
25.0 pAs-1/2

5-HT

C=concentration of O, mol/cm3
D=Diffusion coefficient of O, cm2/s
Conventional voltammetry and microvoltammetry methods
since 1970’s have validated that the flow of charge (current in
amperes) through the surface of indicator is directly proportional to
concentration of electroactive species. Relationship in term of charge,
current, concentration of electroactive species, time, diffusion layer,
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Figure 2: NMI results from resected epileptogenic tissue of hippocampal
Eapp (Volts)
pyramidal layer (Gray matter) in early
neurodegeneration: Monoamines:
Dopamine (DA), Serotonin (5-HT). On the x-axis: oxidation potential in term of
applied voltage in volts (V). On the y-axis: current in picoamperes (pA). Note
that the x-axis terminates at approximately 0.45V due to the low detection limit
of L-tryptophan and neuropeptides in early neurodegeneration.
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biosensors are taken at a cortical micron depth for about 20-30 min
time period.
A classical animal model of PD was used to study endogenous brain
mechanisms of PD in Sprague-Dawley rat (Rattus norvegicus). Depletion
of DA was produced by injecting the neurotoxin, 6-hydoxydopamine
(6-OHDA) into substantia nigra (SN) of male, Sprague-Dawley Rattus
norvegicus in Charles River Laboratories, North Carolina, USA.
This leads to the death of lesioned DA neurons and subsequently to
disruption in dorsal striatum (DStr) and hence depletion of DA in
DStr. The lesion was made in the substantia nigra (SN) of rats under
anesthesia. Stereotaxic coordinates were AP=-1.5, ML=+1.8, DV=7.5
[19].
Another group of animals, same weight (approx. 300 grams) and
age, did not undergo surgery for lesions in SN. These were the controls
or non lesioned groups (Non-PD).
For NMI studies, BRODERICK PROBE® biosensors were
implanted in both PD (lesioned) and non-PD (non-lesioned) animals
in DStr under sodium pentobarbital anesthesia (50 mg/kg ip) [20].
Protocols for NMI studies with PD and non-PD were performed at
Dr. Broderick’s laboratory with approval from the Institutional Animal
Care and Use Committee (IACUC). These studies were performed
to compare endogenous neurochemical profiles of PD and non-PD
animal model.

Detection
Limits-In vivo

Approximate
Neurochemical
Concentration

Catecholamine

DA

2 nM

20 nM

~0.2 nM

Serotonin

5-HT

1 nM

10 nM

~0.5 nM

Homovanillic Acid HVA

20 nM

0.2 µM

7 nM

Tryptophan

L-TP

20 nM

0.2 µM

1 µM

Dynorphin

DYN

4 nM

40 nM

2 µM

Somatostatin

SRIF

3.7 nM

37 nM

4 µM

Table 1: Preliminary data: detection limits for compounds studied intraoperatively.

PD Baseline

Current (nAs-1/2) d1/2 i/dt1/2

NMI studies in PD and non-PD animal model

Detection
Limits-In vitro

Peptide
SRIF

L-Trp
Dyn

5-HT

Results and Discussion

2nA

Clinical studies with epilepsy patient, in situ and in vivo
During early neurodegeneration, monoamines are predominant
in resected epileptogenic tissue of brain (Gray matter) as evident
from NMI results from the BRODERICK PROBE® biosensor. Results
showed a relatively high concentration of DA compared to 5-HT were
present in patient’s hippocampal pyramidal layer of brain. Lauric acid is
a saturated fatty acid with a 12-carbon atom chain. It has a hydrophobic
head with hydrophilic tail which helps to act as a surfactant to reduce
surface tension. This surfactant also acts to assist the migration of
molecules to form an oriented, adsorbed film on the interfacial surface
of the indicator sensor.
Figure 3 depicts recordings from actual human epilepsy neocortex
during intraoperative surgery. Epileptogenic tissue recorded from
0.250

i/A in microamperes (µA)

DYN

0.200

L-TP

0.175

HVA

0.100
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DA/NE

5-HT
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0
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0.200

0.450

0.700
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Figure 3: In vivo, NMI results from actual epilepsy patient studied
intraoperatively showing late neurodegeneration. On the x-axis: oxidation
potential (E/V) in millivolts (mV). On the y-axis: current (i/A) in microamperes.
Minimal concentrations of dopamine (DA), homovanillic acid (HVA), serotonin
(5-HT), and high concentrations of L-tryptophan (L-TP) (precursor to 5-HT),
and neuropeptides (dynorphin and somatostatin) are present.
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Figure 4: NMI results from lesioned group (PD animal model) with endogenous
neurochemical profile. On the x-axis: oxidation potential in term of applied
voltage in volts (V). On the y-axis: current in nanoamperes (nA). NMI was
conducted using the BRODERICK PROBE® laurate biosensor. Serotonin (5HT), L-tryptophan (L-Trp) and neuropeptides (dynorphin and somatostatin)
were present. Note that dopamine (DA) neurotransmitter was absent in
lesioned group (PD).

brain shows late neurodegeneration. A predominance of L-tryptophan
(L-TP) and neuropeptides DYN A and SRIF over monoamines are
observed. Therefore, results show that L-TP and neuropeptides (DYN
A and SRIF) may be biomarkers for neurodegeneration.

Preclinical studies in animal models (PD v/s. non-PD, in situ,
in vivo)

0.150
0.125

0.2

Eapp (Volts)

Intraoperative images were verified by comparison with a fourteen
year empirical database on epilepsy. Table 1 represents preliminary
data of detection limits for different compounds that were studied
intraoperatively using the NMI biotechnology.

SRIF

0.225

0.0

Figure 4 depicts an abundant presence of neurotransmitter
peptides, neuropeptides and a lower concentration of the indoleamine,
5-HT, while DA, expectedly, was not imaged in any PD animal model.
Meanwhile, the non-lesioned group in figure 5 exhibited significant
concentrations of monoamines, DA and 5-HT while neuropeptides
were not observed in any non-PD animal model.

Conclusion
Results showed that the precursor to 5-HT, which is L-TP,
and the neuropeptides DYN A and SRIF may be biomarkers for
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Figure 5: NMI results from controls, the non-lesioned group (Non-PD animal
model) with endogenous neurochemical profile. On the x-axis: oxidation
potential in term of applied voltage in volts (V). On the y-axis: current in
nanoamperes (nA). NMI was conducted using the BRODERICK PROBE®
laurate biosensor. Dopamine (DA), serotonin (5-HT) and L-tryptophan (L-Trp)
were present in high concentration with minimal homovanillic acid (HVA).
Neuropeptides were completely absent in non lesioned group (non-PD).

neurodegeneration. The appearance of L-TP and neuropeptides in
late neurodegeneration of epilepsy patients and in the lesioned group
(PD animal model) support our proposal that neuropeptides appear as
biomarkers of neurodegeneration. We are the first to propose peptide
appearance as biomarker molecule following neurodegeneration in
epilepsy patients and Parkinson’s disease. Furthermore, since DYN A
is comprised of glutamate and SRIF has been shown to alleviate the
symptoms of PD in animal models [20,21], we simply suggest that
DYN A may be the excitatory molecule in neurodegeneration whereas
SRIF may provide neuroprotection in PD. Our findings provide new
avenues for effective diagnoses and detection by using these common
biomarkers against neurodegenerative disorders.
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